Xiaofei F. Yang

No 188, Shizi Street
Suzhou, 215006, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Prognostic significance of CEBPA gene mutations in acute myeloid leukemia

Prognostic significance of CEBPA gene mutations in acute myeloid leukemia

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: July 06, 2026

Real-World Efficacy and Safety of Liposomal Amphotericin B for Invasive Fungal Disease in Patients with Hematologic Malignancies: A Multicenter Retrospective Study.

Real-World Efficacy and Safety of Liposomal Amphotericin B for Invasive Fungal Disease in Patients with Hematologic Malignancies: A Multicenter Retrospective Study.

Journal: Drug design, development and therapy

Published: February 28, 2026

Novel chemical mechanical polishing assisted by photocatalysis and shear-thickening for a free surface blade of a Ti alloy using ceria nano-abrasives.

Novel chemical mechanical polishing assisted by photocatalysis and shear-thickening for a free surface blade of a Ti alloy using ceria nano-abrasives.

Journal: Nanoscale

Published: February 06, 2026

ARHGEF2::JAK2 Fusion Drives Leukemogenesis via CCNB1-Dependent Signaling.

ARHGEF2::JAK2 Fusion Drives Leukemogenesis via CCNB1-Dependent Signaling.

Journal: European journal of haematology

Published: February 03, 2026

Olverembatinib-Based Therapy in Patients With Transformed Chronic Myeloid Leukemia in Lymphoid Blast Phase or Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study.

Olverembatinib-Based Therapy in Patients With Transformed Chronic Myeloid Leukemia in Lymphoid Blast Phase or Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: January 07, 2026

A lower-intensity, venetoclax-containing protocol is effective in adults with newly diagnosed mixedphenotype acute leukemia.

A lower-intensity, venetoclax-containing protocol is effective in adults with newly diagnosed mixedphenotype acute leukemia.

Journal: Haematologica

Published: November 03, 2025

Clinical analysis of six eosinophilia cases with Löeffler endocarditis as the main clinical feature

Clinical analysis of six eosinophilia cases with Löeffler endocarditis as the main clinical feature

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: October 27, 2025

Low initial hemoglobin and high-risk additional chromosomal abnormalities predict poor long-term survival in chronic phase chronic myeloid leukemia.

Low initial hemoglobin and high-risk additional chromosomal abnormalities predict poor long-term survival in chronic phase chronic myeloid leukemia.

Journal: Discover oncology

Published: October 18, 2025

A close atomic surface of stainless steel produced by novel green chemical mechanical polishing using silica and lanthana mixed abrasives.

A close atomic surface of stainless steel produced by novel green chemical mechanical polishing using silica and lanthana mixed abrasives.

Journal: Nanoscale

Published: July 14, 2025

Reduced-dose chemotherapy followed by blinatumomab for newly diagnosed philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: a propensity-matched comparison with hyper-CVAD.

Reduced-dose chemotherapy followed by blinatumomab for newly diagnosed philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia: a propensity-matched comparison with hyper-CVAD.

Journal: Discover oncology

Published: November 06, 2024

Successful combined venetoclax to PD-1 blockade and ruxolitinib for refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.

Successful combined venetoclax to PD-1 blockade and ruxolitinib for refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.

Journal: British journal of haematology

Published: October 14, 2024

Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial.

Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial.

Journal: Journal of hematology & oncology

Published: July 08, 2024

Showing 1-12 of 45

Last Updated: 09/26/2026